Publikationen, an denen er mitarbeitet Luis Bujanda Fernández de Piérola (36)

2024

  1. A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death

    Scientific reports, Vol. 14, Núm. 1, pp. 3000

  2. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  3. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management

    United European Gastroenterology Journal, Vol. 12, Núm. 1, pp. 122-138

  4. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  5. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Gut, Vol. 72, Núm. 11, pp. 2031-2037

  3. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  4. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

    Gut, Vol. 72, Núm. 6, pp. 1054-1072

  5. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  6. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management

    Journal of Clinical Medicine, Vol. 12, Núm. 13

  7. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

2022

  1. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg)

    Journal of Clinical Medicine, Vol. 11, Núm. 12

  2. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257

  3. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study

    Journal of Clinical Medicine, Vol. 11, Núm. 17

  4. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  5. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  6. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)

    Journal of Clinical Gastroenterology, Vol. 56, Núm. 2, pp. E98-E108

  7. V Spanish Consensus Conference on Helicobacter pylori infection treatment

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 392-417

2021

  1. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)

    The American journal of gastroenterology, Vol. 116, Núm. 6, pp. 1220-1229